Skip to main content
. 2022 Aug 26;42(7):1897–1911. doi: 10.1148/rg.220045

Figure 9.

Type 4 lymph node in a 41-year-old woman with no pertinent medical history who presented with palpable concerns in the left axilla 6 days after receiving the second dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in the left arm. (A, B) MLO mammograms of the left breast show axillary lymphadenopathy (arrow in A), which is new from 1 year earlier (arrow in B). (C, D) US images show a type 4 lymph node (arrow in C), which normalized to a type 2 morphology at 6-week follow-up (arrow in D).

Type 4 lymph node in a 41-year-old woman with no pertinent medical history who presented with palpable concerns in the left axilla 6 days after receiving the second dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in the left arm. (A, B) MLO mammograms of the left breast show axillary lymphadenopathy (arrow in A), which is new from 1 year earlier (arrow in B). (C, D) US images show a type 4 lymph node (arrow in C), which normalized to a type 2 morphology at 6-week follow-up (arrow in D).